92 related articles for article (PubMed ID: 32847469)
21. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
PLoS One; 2021; 16(1):e0244995. PubMed ID: 33428635
[TBL] [Abstract][Full Text] [Related]
22. Potential effect modification of RTS,S/AS01 malaria vaccine efficacy by household socio-economic status.
Gyaase S; Asante KP; Adeniji E; Boahen O; Cairns M; Owusu-Agyei S
BMC Public Health; 2021 Jan; 21(1):240. PubMed ID: 33509156
[TBL] [Abstract][Full Text] [Related]
23. The Advanced Development Pathway of the RTS,S/AS01 Vaccine.
von Seidlein L
Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502
[TBL] [Abstract][Full Text] [Related]
24. Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study.
Sauboin CJ; Van Bellinghen LA; Van De Velde N; Van Vlaenderen I
Malar J; 2015 Dec; 14():524. PubMed ID: 26702637
[TBL] [Abstract][Full Text] [Related]
25. Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: Report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa.
Mamotte N; Wassenaar D; Koen J; Essack Z
BMC Med Ethics; 2010 Mar; 11():3. PubMed ID: 20211030
[TBL] [Abstract][Full Text] [Related]
26. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.
Moorthy V; Reed Z; Smith PG;
Vaccine; 2007 Jul; 25(28):5115-23. PubMed ID: 17577487
[TBL] [Abstract][Full Text] [Related]
27. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
[TBL] [Abstract][Full Text] [Related]
28. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01
Chandramohan D; Dicko A; Zongo I; Sagara I; Cairns M; Kuepfer I; Diarra M; Tapily A; Issiaka D; Sanogo K; Mahamar A; Sompougdou F; Yerbanga S; Thera I; Milligan P; Tinto H; Ofori-Anyinam O; Ouedraogo JB; Greenwood B
BMJ Open; 2020 Sep; 10(9):e035433. PubMed ID: 32933955
[TBL] [Abstract][Full Text] [Related]
29. Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.
Hogan AB; Winskill P; Ghani AC
PLoS Med; 2020 Nov; 17(11):e1003377. PubMed ID: 33253211
[TBL] [Abstract][Full Text] [Related]
30. The Ethics of End-of-Trial Obligations in a Pediatric Malaria Vaccine Trial: The Perspectives of Stakeholders From Ghana and Tanzania.
Ward CL; Shaw D; Anane-Sarpong E; Sankoh O; Tanner M; Elger B
J Empir Res Hum Res Ethics; 2018 Jul; 13(3):258-269. PubMed ID: 29756531
[TBL] [Abstract][Full Text] [Related]
31. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
[TBL] [Abstract][Full Text] [Related]
32. Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization.
Moncunill G; Scholzen A; Mpina M; Nhabomba A; Hounkpatin AB; Osaba L; Valls R; Campo JJ; Sanz H; Jairoce C; Williams NA; Pasini EM; Arteta D; Maynou J; Palacios L; Duran-Frigola M; Aponte JJ; Kocken CHM; Agnandji ST; Mas JM; Mordmüller B; Daubenberger C; Sauerwein R; Dobaño C
Sci Transl Med; 2020 May; 12(543):. PubMed ID: 32404508
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
34. Engaging diverse social and cultural worlds: perspectives on benefits in international clinical research from South african communities.
Zvonareva O; Engel N; Ross E; Berghmans R; Dhai A; Krumeich A
Dev World Bioeth; 2015 Apr; 15(1):8-17. PubMed ID: 23725088
[TBL] [Abstract][Full Text] [Related]
35. Development of the RTS,S/AS malaria candidate vaccine.
Vekemans J; Leach A; Cohen J
Vaccine; 2009 Dec; 27 Suppl 6():G67-71. PubMed ID: 20006143
[TBL] [Abstract][Full Text] [Related]
36. Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria.
Wilby KJ; Lau TT; Gilchrist SE; Ensom MH
Ann Pharmacother; 2012 Mar; 46(3):384-93. PubMed ID: 22408046
[TBL] [Abstract][Full Text] [Related]
37. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.
Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I
BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234
[TBL] [Abstract][Full Text] [Related]
38. Towards an African-driven malaria vaccine development program: history and activities of the African Malaria Network Trust (AMANET).
Kilama WL; Chilengi R; Wanga CL
Am J Trop Med Hyg; 2007 Dec; 77(6 Suppl):282-8. PubMed ID: 18165504
[TBL] [Abstract][Full Text] [Related]
39. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease.
Penny MA; Pemberton-Ross P; Smith TA
Malar J; 2015 Nov; 14():437. PubMed ID: 26537608
[TBL] [Abstract][Full Text] [Related]
40. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure.
Kurtovic L; Agius PA; Feng G; Drew DR; Ubillos I; Sacarlal J; Aponte JJ; Fowkes FJI; Dobaño C; Beeson JG
BMC Med; 2019 Feb; 17(1):45. PubMed ID: 30798787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
